Shopping Cart 0
Cart Subtotal
AED 0

Shionogi Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co., Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address the unmet medical needs. The company offers a wide range of branded prescription products to treat chronic diseases. It markets products for various therapeutic areas such as pain, anti-infectives, women's health, pediatrics, cardiovascular and others. Shionogi offers its products in various formulations such as tablets, oral suspensions (solutions), lotions, capsules, chewable tablets and injections. Some of the company's key branded products include Doribax, Fortamet, Methylin, Ponstel and Xodol, among others. Shionogi is headquartered in Florham Park, New Jersey, the US.

Shionogi Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Shionogi Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Shionogi Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Shionogi Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 11

Licensing Agreements 12

Pharmbio Korea Enters into Licensing Agreement with Shionogi 12

Duchesnay Receives Rights for Osphena from Shionogi 13

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 14

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 15

Equity Offering 16

PharmaIN to Raise USD17 Million in Private Placement of Shares 16

Asset Transactions 17

Pragma Pharma Acquires Keflex from Shionogi 17

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 18

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 19

Merz Pharma Acquires Cuvposa from Shionogi 20

Shionogi Inc-Key Competitors 21

Shionogi Inc-Key Employees 22

Shionogi Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Corporate Communications 24

May 09, 2018: Shionogi to Announce Executive Appointment 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Shionogi Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Shionogi Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Shionogi Inc, Pharmaceuticals & Healthcare, Key Facts 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Shionogi Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Shionogi Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Shionogi Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 11

Pharmbio Korea Enters into Licensing Agreement with Shionogi 12

Duchesnay Receives Rights for Osphena from Shionogi 13

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 14

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 15

PharmaIN to Raise USD17 Million in Private Placement of Shares 16

Pragma Pharma Acquires Keflex from Shionogi 17

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 18

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 19

Merz Pharma Acquires Cuvposa from Shionogi 20

Shionogi Inc, Key Competitors 21

Shionogi Inc, Key Employees 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co., Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address the unmet medical needs. The company offers a wide range of branded prescription products to treat chronic diseases. It markets products for various therapeutic areas such as pain, anti-infectives, women's health, pediatrics, cardiovascular and others. Shionogi offers its products in various formulations such as tablets, oral suspensions (solutions), lotions, capsules, chewable tablets and injections. Some of the company's key branded products include Doribax, Fortamet, Methylin, Ponstel and Xodol, among others. Shionogi is headquartered in Florham Park, New Jersey, the US.

Shionogi Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Shionogi Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Shionogi Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Shionogi Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 11

Licensing Agreements 12

Pharmbio Korea Enters into Licensing Agreement with Shionogi 12

Duchesnay Receives Rights for Osphena from Shionogi 13

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 14

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 15

Equity Offering 16

PharmaIN to Raise USD17 Million in Private Placement of Shares 16

Asset Transactions 17

Pragma Pharma Acquires Keflex from Shionogi 17

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 18

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 19

Merz Pharma Acquires Cuvposa from Shionogi 20

Shionogi Inc-Key Competitors 21

Shionogi Inc-Key Employees 22

Shionogi Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Corporate Communications 24

May 09, 2018: Shionogi to Announce Executive Appointment 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Shionogi Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Shionogi Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Shionogi Inc, Pharmaceuticals & Healthcare, Key Facts 2

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Shionogi Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Shionogi Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Shionogi Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Shionogi Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 11

Pharmbio Korea Enters into Licensing Agreement with Shionogi 12

Duchesnay Receives Rights for Osphena from Shionogi 13

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 14

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 15

PharmaIN to Raise USD17 Million in Private Placement of Shares 16

Pragma Pharma Acquires Keflex from Shionogi 17

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 18

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 19

Merz Pharma Acquires Cuvposa from Shionogi 20

Shionogi Inc, Key Competitors 21

Shionogi Inc, Key Employees 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS